Skip to content

Clinical Study on Treatment of Chronic Kidney Disease with Bailing Capsule at Different Dosage

Clinical Study on Treatment of Chronic Kidney Disease with Bailing Capsule at Different Dosage

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17014157
Enrollment
Unknown
Registered
2017-12-26
Start date
2018-01-01
Completion date
Unknown
Last updated
2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

Control group:Basic treatment
Bailing capsule low-dose group:Bailing capsule: 3g /d
Bailing capsule high dose group:Bailing capsule: 9g /d

Sponsors

Longhua Hospital, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Aged 18 to 70 years old; (2) CKD patients eGFR 15 to 60ml/min.1.73m2. (3) sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) poor compliance, can not be followed up on schedule; (2) are participating in interventional clinical trials; (3) patients with acute kidney injury (AKI), that is, serum creatinine increased within 48 hours = 0.3mg/dl; or within 7 days serum creatinine more than 1.5 times the baseline value; or urine output <0.5ml / kg / h greater than 6 hours. (4) Previously received organ or bone marrow transplantation; (5) There are active or metastatic tumors within 2 years before screening; (6) Expected life expectancy <6 months; (7) Severe cardiac insufficiency (NYHA class III or IV heart failure, that is, with underlying heart disease, body Force activities were significantly limited, less than normal physical activity or even resting state can be tired, palpitations, asthma Or angina pectoris); (8) HIV infection or AIDS; (9) there is dementia or other mental disorders, physical activity is limited, severe visual impairment can not match complete the assessment; (10) patients undergoing immunosuppressive therapy.

Design outcomes

Primary

MeasureTime frame
Glomerular filtration rate;24-hour urine protein quantitation;

Countries

China

Contacts

Public ContactYueyi Deng

Longhua Hospital, Shanghai University of Traditional Chinese Medicine

wxf19900110@126.com+86 18917763063

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026